Long-term cholesterol medicines after heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This trial studies how well long-term cholesterol-lowering treatment works in people who recently had a heart attack (STEMI or NSTEMI). It may help your care team understand which patients benefit most and how treatment should be continued safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a recent heart attack called STEMI or NSTEMI, confirmed by ECG and blood tests (troponin I and CPK-MB) plus a heart scan of the arteries
- Your heart artery scan shows an artery connected to the heart attack
- You do not have major narrowing in multiple coronary arteries (over 30%)
- You have not had another heart attack again recently
- You can take cholesterol medicines: you are not intolerant to statins or ezetimibe
- You do not have certain health problems (for example: advanced kidney disease, uncontrolled blood pressure, severe anemia, or major rhythm/heart conduction problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.
This study compares two cholesterol treatment approaches after a heart attack: a lower dose combination versus a higher dose single medicine. It aims to see which option works well and is tolerable for people after a treated heart attack.
This study tests whether a newer cholesterol-lowering injection, given early after a heart attack, helps keep the plaque in your arteries stable and reduces future risk. It compares the new medicine added to your usual statin treatment.
This study tests whether starting a cholesterol-lowering injection (a PCSK9 inhibitor) early after a heart attack can slow or shrink the buildup of plaque in other heart arteries that are not the one that was stented. If you have two other arteries with mild blockages, this treatment might help prevent future heart problems.
This study tests whether adding an extra cholesterol-lowering drug (bempedoic acid) to the usual treatment soon after a heart attack or related event can lower 'bad' cholesterol more effectively. It may help reduce the risk of future heart problems.
This study compares two approaches to lowering 'bad' cholesterol (LDL-C) in people hospitalized with acute coronary syndrome (a heart attack or unstable angina). One approach uses two medications (a statin plus another pill), and the other uses three (adding an injectable medicine). The goal is to see if the triple therapy lowers cholesterol more effectively and helps prevent future heart problems.
Hear when a new Arterial Stiffness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.